Nippon Shinyaku and Taiho strike itching product alliance
This article was originally published in Scrip
Nippon Shinyaku has licensed an early-stage pipeline product for serious itching to Taihofor co-development and co-marketing in Japan. The compound, NS-141, is still at the preclinical stage and represents a new approach to serious itching related to disorders such as atopic dermatitis, Nippon Shinyaku said. Taiho will make undisclosed up front, milestone and royalty payments as part of the deal and will join the development programme from Phase I.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.